Jeffrey S. Ward

608.280.6751 | Email | vCard  |  Biography

Madison Office

10 East Doty Street
Suite 600
Madison, WI 53703

xx ph: 608.280.6750 fax: 612.332.9081

Assistant:

Julie King
jking@merchantgould.com
608.280.67461

Education

Court Admissions

Notable Cases

Jeffrey S. Ward is a partner in the Madison Office and is a member of the firm's litigation practice group. Mr. Ward has concentrated his practice on the representation of generic pharmaceutical companies, including Hatch-Waxman litigation, over the past 20 years. His practice focuses primarily in the area of patent litigation, opinion work, and client counseling. Mr. Ward has litigated patent disputes relating to the pharmaceutical, chemical and mechanical arts in federal courts throughout the United States and in the United States International Trade Commission.

Mr. Ward has represented several generic pharmaceutical companies and API manufacturers providing advice with respect to Abbreviated New Drug Applications (ANDA) submissions. Mr. Ward has also acted as lead counsel in several Hatch-Waxman litigations matters.

During his career, Mr. Ward has participated in many significant intellectual property law cases. He was a member of the team that argued Morton-International v. Cardinal Chemical, one of the few patent cases heard by the U.S. Supreme Court in recent years. During that case, the Supreme Court directed the Court of Appeals for the Federal Circuit to change the way in which it reviewed patent cases on appeal.

Education

J.D., 1984

University of Illinois
B.S., Chemical Engineering, cum laude, 1981


Court Admissions

U.S. Supreme Court
U.S. Court of Appeals, Federal Circuit
U.S. District Court, Eastern District of Michigan
U.S. District Court, Northern District of Illinois (including Trial Bar)
U.S. District Court, Western District of Wisconsin
U.S. District Court, Central District of Illinois
U.S. District Court, District of Colorado

Notable Cases

In re: Rosuvastatin Calcium Patent Litigation, MDL No. 08-1949 (D. Del.)

AstraZeneca Pharmaceuticals LP et al v. Aurobindo Pharma Limited, Inc. et al, No. 07-810 (D. Del.)

Future Fibre Technologies Pty. Ltd. v. Optellios, Inc., No. 08-CV-600 (MD. Fla.)

Riezler et al v. Allen et al, No. 08-CV-332 (D. Colo.)

Invitrogen Corporation v. Oxford Biomedical Research, Inc. and Vanderbilt University, No. 08-CV-599 (W.D. Wis.)

Z Trim Holdings, Inc. v. Fiberstar, Inc., No. 07-CV-161 (W.D. Wis.)

Z Trim Holdings, Inc. v. Fiberstar, Inc., No. 06-CV-361 (W.D. Wis.)

Forest Laboratories, Inc. v. Ivax Pharmaceuticals, Inc., et al, 438 F. Supp. 3d 479 (D. Del. 2006)

Medichem S.A. v. Rolabo, S.L., 437 F.3d 1157 (Fed. Cir. 2006)

Eli Lilly & Co. v. Zenith Goldline Pharms., Inc., 364 F. Supp. 2d 820 (S.D. Ind. 2005)

Glaxo, Inc. v. Novopharm Ltd., 931 F. Supp. 1280 (E.D.N.C.1996)

Kraft Foods, Inc. v. Int'l. Trading Co., 203 F.3d 1362 (Fed. Cir. 2000)

Glaxo, Inc. v. Novopharm Ltd., 52 F.3d 1043 (Fed. Cir. 1995)

Burroughs Wellcome Co. v. Barr Labs., 40 F.3d 1223 (Fed. Cir. 1994)

Pall Corp. v. Micron Separations, Inc., 66 F.3d 1211 (Fed. Cir. 1995)

Cardinal Chemical Co. v. Morton Int'l, Inc.; 508 U.S. 83 (1993)